Danaher Co. (NYSE:DHR) Shares Bought by Cetera Advisors LLC

Cetera Advisors LLC grew its position in Danaher Co. (NYSE:DHR) by 44.3% during the first quarter, Holdings Channel reports. The firm owned 27,346 shares of the conglomerate’s stock after acquiring an additional 8,389 shares during the period. Cetera Advisors LLC’s holdings in Danaher were worth $6,829,000 as of its most recent filing with the SEC.

Several other institutional investors have also recently modified their holdings of the company. Cape Investment Advisory Inc. acquired a new stake in Danaher during the 4th quarter valued at approximately $25,000. Tsfg LLC lifted its position in Danaher by 733.3% during the first quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock valued at $25,000 after purchasing an additional 88 shares during the period. Wetzel Investment Advisors Inc. purchased a new stake in Danaher in the fourth quarter valued at $29,000. Redmont Wealth Advisors LLC acquired a new stake in Danaher during the 1st quarter worth about $30,000. Finally, Rakuten Securities Inc. purchased a new position in shares of Danaher during the 4th quarter valued at about $36,000. 79.05% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Danaher

In related news, CFO Matthew Mcgrew sold 46,377 shares of the firm’s stock in a transaction dated Friday, May 10th. The shares were sold at an average price of $253.05, for a total transaction of $11,735,699.85. Following the completion of the sale, the chief financial officer now directly owns 29,407 shares in the company, valued at $7,441,441.35. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. In related news, CFO Matthew Mcgrew sold 46,377 shares of the stock in a transaction that occurred on Friday, May 10th. The stock was sold at an average price of $253.05, for a total value of $11,735,699.85. Following the completion of the transaction, the chief financial officer now directly owns 29,407 shares in the company, valued at $7,441,441.35. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Rainer Blair sold 19,085 shares of Danaher stock in a transaction on Tuesday, May 14th. The shares were sold at an average price of $255.00, for a total value of $4,866,675.00. Following the completion of the sale, the chief executive officer now owns 115,995 shares in the company, valued at approximately $29,578,725. The disclosure for this sale can be found here. Insiders sold a total of 113,174 shares of company stock worth $29,775,644 in the last three months. 11.10% of the stock is owned by corporate insiders.

Danaher Price Performance

Shares of Danaher stock traded down $4.01 during trading hours on Friday, reaching $276.75. 3,108,808 shares of the company’s stock were exchanged, compared to its average volume of 3,183,765. The business has a fifty day moving average of $256.29 and a two-hundred day moving average of $250.77. The company has a quick ratio of 1.04, a current ratio of 1.43 and a debt-to-equity ratio of 0.33. The company has a market capitalization of $199.87 billion, a P/E ratio of 46.91, a price-to-earnings-growth ratio of 4.62 and a beta of 0.83. Danaher Co. has a 1 year low of $182.09 and a 1 year high of $281.70.

Danaher (NYSE:DHR) last announced its quarterly earnings data on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.57 by $0.15. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The company had revenue of $5.74 billion during the quarter, compared to analysts’ expectations of $5.59 billion. During the same quarter in the prior year, the company earned $2.05 EPS. Danaher’s revenue was down 2.9% compared to the same quarter last year. As a group, research analysts predict that Danaher Co. will post 7.59 earnings per share for the current fiscal year.

Danaher Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, July 26th. Shareholders of record on Friday, June 28th were paid a dividend of $0.27 per share. This represents a $1.08 dividend on an annualized basis and a yield of 0.39%. The ex-dividend date was Friday, June 28th. Danaher’s dividend payout ratio (DPR) is currently 18.31%.

Wall Street Analyst Weigh In

DHR has been the topic of a number of recent research reports. Evercore ISI lowered their target price on Danaher from $266.00 to $260.00 and set an “outperform” rating on the stock in a research note on Tuesday, July 2nd. Royal Bank of Canada upped their price objective on Danaher from $297.00 to $300.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 24th. The Goldman Sachs Group lifted their target price on shares of Danaher from $225.00 to $250.00 and gave the company a “neutral” rating in a report on Wednesday, July 24th. Citigroup increased their price target on shares of Danaher from $280.00 to $290.00 and gave the stock a “buy” rating in a report on Wednesday, April 24th. Finally, Bank of America lifted their price objective on shares of Danaher from $270.00 to $275.00 and gave the company a “neutral” rating in a report on Wednesday, July 24th. Six analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $276.88.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.